REXAHN PHARMACEUTICALS INC DEF 14A 6-18-2012

Company

Opus Genetics, Inc.

Filed

April 26, 2012

Period of Report

June 18, 2012

Accession Number

0001140361-12-021555

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →